AB2056

Anti-TRAIL antibody

Name: Anti-TRAIL antibody (ab2056) | Abcam
Brand: Abcam Limited
SKU: AB2056
Price: 525 USD
Availability: InStock

Be the first to review this product! Submit a review

(10 Publications)

Rabbit Polyclonal TRAIL antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 10 publications. Immunogen corresponding to Synthetic Peptide within Human TNFSF10 aa 250 to C-terminus.

View Alternative Names

CD253, APO2L, TRAIL, TNFSF10, Tumor necrosis factor ligand superfamily member 10, Apo-2 ligand, TNF-related apoptosis-inducing ligand, Apo-2L, Protein TRAIL

4 Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRAIL antibody (AB2056)

IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRAIL antibody (AB2056)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) of human brain tissue staining TRAIL with ab2056 at 20µg/ml

IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRAIL antibody (AB2056)

Immunohistochemistry of TRAIL in human brain tissue with TRAIL antibody at 20 µg/ml.

Unknown

Western blot - Anti-TRAIL antibody (AB2056)

Western blot analysis of HeLa cell lysate containing 10, 2.5, or 1 ng of recombinant protein including extracellular domain of TRAIL with anti-TRAIL at 1 µg/ml Western blot analysis of HeLa cell lysate containing 10, 2.5, or 1 ng of recombinant protein containing extracellular domain of TRAIL with anti-TRAIL at 1 µg/ml.

All lanes:

Western blot - Anti-TRAIL antibody (ab2056)

Predicted band size: 32 kDa

false

Unknown

Western blot - Anti-TRAIL antibody (AB2056)

Western Blot of human brain lysate labeling TRAIL with Anti-TRAIL antibody (ab2056) at (1) 2.5 and (2) 5 μg/ml.

All lanes:

Western blot - Anti-TRAIL antibody (ab2056)

Predicted band size: 32 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

Reacts with

Human

Applications

IHC-P, WB

applications

Immunogen

Synthetic Peptide within Human TNFSF10 aa 250 to C-terminus. The exact immunogen used to generate this antibody is proprietary information.

P50591

style

left-column

Alternative Products

Primary Antibodies

AB9959

Anti-TRAIL antibody

Sandwich ELISA - Anti-TRAIL antibody (AB9959)

Primary Antibodies

AB2219

Anti-TRAIL antibody [2E5]

Advanced Validation

Functional Studies - Anti-TRAIL antibody [2E5] (AB2219)

Primary Antibodies

AB95532

PE Anti-TRAIL antibody [N2B2]

Flow Cytometry - PE Anti-TRAIL antibody [N2B2] (AB95532)

Primary Antibodies

AB42121

Anti-TRAIL antibody

BOND RX™ Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRAIL antibody (AB42121)

Primary Antibodies

AB231063

Anti-TRAIL antibody

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRAIL antibody (AB231063)

Complementary Products

Assay Kits

AB46074

Human TRAIL ELISA Kit (CD253)

ELISA - Human TRAIL ELISA Kit (CD253) (AB46074)

Primary Antibodies

AB8416

Anti-DR5 antibody

Immunocytochemistry - Anti-DR5 antibody (AB8416)

Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

Primary Antibodies

AB9485

Anti-GAPDH antibody - Loading Control

BOND RX™ Validated|Lab Essentials

Primary Antibodies

AB8227

Anti-beta Actin antibody - Loading Control

BOND RX™ Validated|Lab Essentials

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500", "WB-species-notes": "<p>Gives a 32 kD band which represents the membrane-bound form of TRAIL.</p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "20 µg/mL", "IHCP-species-notes": "<p></p>" } } }

style

left-column

Product details

Ligand for DR4 and DR5.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification

Storage buffer

pH: 7.2 Preservative: 0.02% Sodium azide

Shipped at conditions

Blue Ice

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TRAIL also known as TNF-related apoptosis-inducing ligand plays an important role in inducing apoptosis. This protein has a mass of around 32 kDa and is expressed across various tissues including immune cells. TRAIL interacts with specific receptors on the cell surface to initiate a signaling cascade that results in programmed cell death. It is an attractive therapeutic target because of its selective ability to induce apoptosis in cancer cells while sparing most normal cells.

Biological function summary

TRAIL's function extends beyond inducing cell death. It is an important member of the tumor necrosis factor (TNF) superfamily which regulates immune responses and inflammation. TRAIL can form a homotrimeric complex allowing it to bind effectively to death receptors on target cells specifically DR4 and DR5 triggering a series of downstream signaling events. This interaction is significant in modulating immune surveillance and tumor suppression.

Pathways

TRAIL is integral to both intrinsic and extrinsic apoptosis pathways. Through these pathways TRAIL is closely related to FADD and caspase-8 which are important for apoptosis induction. The extrinsic pathway involves binding to TRAIL death receptors leading to DISC formation while the intrinsic pathway involves mitochondrial events mediated by members of the Bcl-2 protein family.

TRAIL has a significant connection with cancer and autoimmune diseases. TRAIL plays a dual role in cancer where it acts as a tumor suppressor but can also promote tumor progression if cancer cells become resistant to its effects. In cancer TRAIL’s interaction with proteins like FLIP can alter the apoptotic potential of the cells. In autoimmune diseases TRAIL's dysregulation can contribute to tissue damage due to increased immune activity highlighting its complex role in maintaining immune balance.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG (PubMed : 10549288, PubMed : 26457518). Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis.

See full target information TNFSF10

style

left-column

Publications (10)

Recent publications for all applications. Explore the full list and refine your search

Cancer immunology, immunotherapy : CII 74:47 PubMed39751958

2025

Distinct immune signatures for predicting the immunotherapy efficacy of esophageal squamous cell carcinoma or adenocarcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Peng Wu,Guohui Qin,Jinyan Liu,Qitai Zhao,Xueke Zhao,Xin Song,Lidong Wang,Shengli Yang,Yi Zhang

Discover oncology 15:45 PubMed38383815

2024

TRAIL predisposes non-small cell lung cancer to ferroptosis by regulating ASK-1/JNK1 pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaofang Liu,Huiqian Deng,Mi Huang,Wei Zhou,Yilin Yang

Scientific reports 14:946 PubMed38200037

2024

Optimization of extracellular vesicles preparation from saliva of head and neck cancer patients.

Applications

Unspecified application

Species

Unspecified reactive species

Luisa Tengler,Moritz Tiedtke,Julia Schütz,Karen Bieback,Stefanie Uhlig,Marie-Nicole Theodoraki,Katja Nitschke,Thomas Stefan Worst,Elena Seiz,Claudia Scherl,Nicole Rotter,Sonja Ludwig

International journal of oncology 63: PubMed37503786

2023

Modulation of PD‑L1 expression by standard therapy in head and neck cancer cell lines and exosomes.

Applications

Unspecified application

Species

Unspecified reactive species

Annette Affolter,Kai Liebel,Luisa Tengler,Elena Seiz,Moritz Tiedtke,Alexya Azhakesan,Julia Schütz,Marie-Nicole Theodoraki,Johann Kern,Arne M Ruder,Jens Fleckenstein,Cleo-Aron Weis,Karen Bieback,Benedikt Kramer,Anne Lammert,Claudia Scherl,Nicole Rotter,Sonja Ludwig

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 34:211-220 PubMed36511604

2022

Raw Lacquer Extract from Toxicodendron vernicifluum in Combination with ONC201 Enhances the Inhibitory Effects on Colorectal Cancer Cell Activity.

Applications

Unspecified application

Species

Unspecified reactive species

Zhezhu Jin,Yongjun Jin

Marine drugs 20: PubMed36286419

2022

Cytotoxic Potential of the Marine Diatom : Insights into Bioactivity of 24-Methylene Cholesterol.

Applications

Unspecified application

Species

Unspecified reactive species

Adele Cutignano,Mariarosaria Conte,Virginia Tirino,Vitale Del Vecchio,Roberto De Angelis,Angela Nebbioso,Lucia Altucci,Giovanna Romano

Cancers 13: PubMed33922569

2021

Small Extracellular Vesicles in Pre-Therapy Plasma Predict Clinical Outcome in Non-Small-Cell Lung Cancer Patients.

Applications

Unspecified application

Species

Unspecified reactive species

Eleni-Kyriaki Vetsika,Priyanka Sharma,Ioannis Samaras,Alexandra Markou,Vassilis Georgoulias,Theresa L Whiteside,Athanasios Kotsakis

Oncotarget 9:27233-27241 PubMed29930761

2018

Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations.

Applications

Unspecified application

Species

Unspecified reactive species

Matias Eliseo Melendez,Renato José Silva-Oliveira,Anna Luiza Silva Almeida Vicente,Lidia Maria Rebolho Batista Arantes,Ana Carolina de Carvalho,Alberto Luis Epstein,Rui Manuel Reis,André Lopes Carvalho

Clinical cancer research : an official journal of the American Association for Cancer Research 23:4843-4854 PubMed28400428

2017

Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Sonja Ludwig,Theofanis Floros,Marie-Nicole Theodoraki,Chang-Sook Hong,Edwin K Jackson,Stephan Lang,Theresa L Whiteside

Oncology reports 27:39-44 PubMed21993926

2011

TRAIL produced from multiple myeloma cells is associated with osteolytic markers.

Applications

Unspecified application

Species

Unspecified reactive species

Yawara Kawano,Shikiko Ueno,Masahiro Abe,Yoshitaka Kikukawa,Hiromichi Yuki,Kenichi Iyama,Yutaka Okuno,Hiroaki Mitsuya,Hiroyuki Hata

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com